199 related articles for article (PubMed ID: 17577027)
1. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
[TBL] [Abstract][Full Text] [Related]
2. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
Zambetti M; Bonadonna G; Valagussa P; Daidone MG; Coradini D; Bignami P; Contesso G; Silvestrini R
J Natl Cancer Inst Monogr; 1992; (11):77-83. PubMed ID: 1627434
[TBL] [Abstract][Full Text] [Related]
4. [Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group].
Untch M
Zentralbl Gynakol; 1998; 120(6):284-92. PubMed ID: 9659699
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ
Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic and therapeutic significance of steroid receptors in invasive breast cancer].
Wyss P; Rageth JC; Unger C; Hochuli E
Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):611-6. PubMed ID: 1294437
[TBL] [Abstract][Full Text] [Related]
10. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
11. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes.
Ludwig Breast Cancer Study Group
Cancer Res; 1985 Sep; 45(9):4454-9. PubMed ID: 2862995
[TBL] [Abstract][Full Text] [Related]
13. [Ovarian function and recurrence in adjuvant chemotherapy of breast cancer].
Schmidt-Gollwitzer K; Schönegg W; Scheiber A; Wessel J
Geburtshilfe Frauenheilkd; 1987 Oct; 47(10):695-9. PubMed ID: 3678786
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
16. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Ruffert K
Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
[TBL] [Abstract][Full Text] [Related]
17. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1996 Jun; 14(6):1885-94. PubMed ID: 8656257
[TBL] [Abstract][Full Text] [Related]
18. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
Bonadonna G; Rossi A; Tancini G; Bajetta E; Marchini S; Brambilla C; Tesoro Tess JD; Valagussa P; Banfi A; Veronesi U
Cancer Treat Rep; 1981; 65 Suppl 1():61-5. PubMed ID: 7034930
[TBL] [Abstract][Full Text] [Related]
20. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
Bianco AR; De Placido S; Pagliarulo C; Fasano S; D'Istria M; De Sio L; Ricciardi I; Delrio G
Chemioterapia; 1985 Jun; 4(3):252-5. PubMed ID: 3839720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
